Genetic Testing for Hereditary Neuropathies: How Next-Generation Sequencing Is Changing Diagnosis and Family Risk Assessment

When “Idiopathic” Isn’t Really Idiopathic

Every neurologist has that one patient whose chart says “idiopathic neuropathy” in big letters even after years of testing. Then one day, often five or ten years in, a genetic panel lights up with a PMP22 duplication or MFN2 variant. Turns out it wasn’t idiopathic at all, it was Charcot-Marie-Tooth type 1A, hiding in plain sight the whole time. That’s what next-generation sequencing (NGS) is doing to our old categories. Frankly, it’s killing the word “idiopathic.”

Just a few years ago, diagnosing hereditary neuropathies meant chasing single-gene tests. We guessed based on clinical pattern: demyelinating or axonal, childhood onset or adult, family history or sporadic. Miss the guess, and insurance refused to cover the test. Now we can screen hundreds of nerve-related genes at once, fast and relatively cheap. Panels launched in 2024 commonly include over 100 genes, from the usual suspects PMP22, MPZ, and GJB1 to more obscure players like SH3TC2, POLG, or FIG4. The upshot: far more of these “mystery” neuropathies now have a name.

What Next-Generation Sequencing Actually Sees

NGS isn’t one test. It’s a set of technologies that shred DNA into fragments, read them all simultaneously, then stitch the sequences back together to spot variations. For neuropathy, most labs use targeted panels of known peripheral nerve genes. Others go straight to whole-exome sequencing (WES) or even whole-genome sequencing (WGS). Think of Sanger sequencing as reading one page at a time. NGS reads the whole library in one sitting.

The results aren’t always tidy. Roughly one-third of patients with suspected hereditary neuropathy get a “variant of uncertain significance.” That means the lab found something, but its meaning’s still unclear. The research is mixed here. Databases keep improving, but it still takes a clinician who recognizes phenotypes to interpret real impact. So before ordering testing, make sure a neurogenetics clinic, not a direct-to-consumer lab with marketing gloss, is in the loop. This isn’t just about data; it’s about context.

When the answer’s clear, it can change everything. Identifying an MPZ or MFN2 mutation might explain that subtle gait change your patient’s father also had. A PMP22 duplication locks in a diagnosis of CMT1A, the classic demyelinating neuropathy behind about half of hereditary cases. But a TTR variant? Whole different story, it signals familial amyloid polyneuropathy, treatable with medications like tafamidis or patisiran. Miss it and you risk more than foot numbness, you risk heart and organ involvement. Catch it early and that’s a life you can change.

How the Family Feels It

I once cared for a 42-year-old accountant, no diabetes, told his burning feet were “probably idiopathic small fiber neuropathy.” Normal EMG. Skin biopsy showed fiber loss. He’d lived that way for eight years collecting creams and gabapentin prescriptions. We eventually ran a sensory neuropathy panel, it flagged a nonsense mutation in SCN9A. That changed everything. His two teenagers now know their risk; his brother, with unexplained tingling for years, tested positive too. Molecular confirmation turned an isolated problem into something the family could actually plan around.

But families aren’t predictable. Some carriers barely notice symptoms while others are disabled by them. That difference, penetrance, is exactly why early counseling matters. When a variant turns up, a genetic counselor can walk through inheritance patterns, reproductive choices, and what kind of monitoring to set up. These aren’t theoretical exercises anymore. Guidelines now recommend offering testing to relatives whenever a clearly pathogenic variant appears. Track the disease before it shows itself and you might preserve mobility well into middle age instead of losing it by 30. That’s worth the effort.

Of course, not every variant equals disease. Labs now filter results more carefully, and older reports need review. Some variants once labeled “pathogenic” have since been downgraded after better population data came out. If your genetic results are more than five years old, ask for a second look. The science doesn’t stand still.

Thinking About Testing

Not every numb toe calls for sequencing. If the likely cause is diabetes, alcohol, or chemo, testing won’t add much. But when neuropathy starts young, runs in families, or the EMG shows uniform slowing out of proportion to known risks, genetics deserves a place on the shortlist. Especially in cases where symptoms began in childhood or adolescence, then it’s worth referral to a neurologist who knows inherited neuropathies or a tertiary neurogenetics clinic. They see the patterns the rest of us could miss.

Let’s be practical. Insurance usually covers testing when your neurologist documents reasonable suspicion and family history. Out-of-pocket cost is falling fast; many panels are now under $1,000. Some services even offer reflex testing, if the panel’s negative, they automatically move to exome-level sequencing with your consent. Saves time, sometimes months. And time matters for family planning, career choices, even which meds to avoid.

What I wouldn’t recommend: letting your primary doctor order a generic “neuropathy panel” without pretest counseling. Genes like TTR and MPZ have broader implications, cardiac or otherwise. Before you agree to testing, ask who’ll interpret it and whether a genetic counselor is involved. If the answer’s shrugging or vague, find a clinic that handles these cases routinely. No shame in that, this stuff is complex.

The Road Ahead

We now know of more than 120 genes linked to hereditary neuropathies, and that number keeps growing. Artificial intelligence is already pairing electrodiagnostic data with gene variants to refine diagnoses. Drug development’s finally catching up, with targeted therapies not just for TTR amyloidosis but for certain CMT subtypes. Early gene-silencing and repair trials are underway. And all of it depends on getting the genetic diagnosis right first.

So, about that “idiopathic neuropathy.” The label feels outdated. NGS has changed the landscape. If you or your patient has a long-standing unexplained neuropathy, this is the moment to look again. The data’s here. Someone just has to read it.